PRP results vary because “PRP” is not one product. What reaches the joint or tendon depends on the platelet dose really given and on how the concentrate was made. Both differ widely between protocols. A 2025 review in the Journal of Clinical Medicine looked at PRP in sports medicine. It covered osteoarthritis, tendon problems, and muscle injury. It reports that the best results come when doses top 3.5 billion platelets per shot. The best results also came with total doses of 10 to 12 billion across several treatments.
What “PRP dose” means when two preparations are compared
Patients usually assume PRP is one product with one dosing standard. In practice, the dose is set by how it is processed and by what is measured in the final concentrate. It is not set by the label on the treatment.
That is why two shots both called PRP can deliver very different numbers of platelets to the same target.
Dose can be defined three different ways
Protocols state a dose in one of three ways. It may be platelets per microliter, platelets per shot, or total platelets across a course. A prep that meets one of those will not always meet another.
The review above notes that many studies report only platelet concentration or how many times it was boosted. They do not report the actual number of platelets. That is exactly why the three definitions get mixed up. The practical question to ask any clinic is this. What is the final platelet dose, how is it defined, and is it measured or assumed?
Does the way PRP is prepared change the results?
Leukocyte-rich versus leukocyte-poor
White cell content is not a minor detail. It shapes the inflammation signals in the treated tissue. Protocols pick a white cell profile on purpose, based on the target.
For shots into the joint, the same 2025 review reports that leukocyte-poor PRP, which has fewer neutrophils, works better than leukocyte-rich PRP. The authors also note that for tendons and muscles the question is still debated. So the joint finding should not be applied to every site.
Red blood cell contamination and pre-activation
The same review names two things that make PRP work worse. One is red blood cells mixed in. The other is activating it too early. On that basis, it argues for standard prep protocols. If a concentrate is activated before it is placed, or carries a lot of red cells, it does not behave the way the protocol assumed.
How it is made makes a measurable difference here. A randomized study of 150 patients with knee osteoarthritis came out in Scientific Reports in 2021. Adding a 1 micron filter step to hand-made PRP raised platelet recovery to as much as 90%. The same blood, made differently, gives a different shot.
Why do PRP studies show such mixed results?
Patients reading the research find conflicting results. They fairly conclude that PRP is unpredictable. A large part of that mix-up is a reporting problem, not a biology problem.
The 2025 review shows that few of the PRP trials it studied fully described their method. Only about a quarter reported PRP makeup in numbers. When the treatment is not described, two trials with the same label may have given very different products.
Methodological quality compounds it
The same review reports a study of PRP papers. A large share had errors in their methods, and a real share were judged unreliable. Uneven measuring and reporting make results look less predictable than the biology may really be.
In practice, we treat a PRP course as a process with checkpoints, not a single event with a verdict.
Why can PRP fail even when the dose is right?
PRP is not injected into empty space. Even with dose and prep under control, the tissue it lands in is shaped by your whole-body metabolic health.
When joint pain tracks with metabolic stress instead of with activity, treating only the local target tends to give short-lived results. That idea is laid out in our writing on the biological terrain. It is why the metabolic work runs alongside any shot, not after it.
Structural stage sets the ceiling
When imaging shows advanced disease, the realistic goal changes. In advanced knee osteoarthritis we frame PRP the way the practice positions it: a safe bridge therapy before joint replacement. We do not claim it regrows cartilage. Conservative care comes first. When it has truly run its course, surgery is available here. Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon.
Does it matter where the PRP is injected?
Where the concentrate is placed decides what it can act on. Intraosseous PRP aims at signals near the bone marrow. Subchondral PRP is placed near the bone just under the cartilage, which carries the joint’s load. Both are chosen to test a specific medical idea about the pain source. They are not upgrades to a standard shot.
The same logic decides when we use bone marrow aspirate concentrate, Lipogems, or shots into the disc instead. Each is a different tool with a different target. The question “was this delivered to the target that matches the hypothesis?” belongs next to the dose question.
What should you ask before getting a PRP injection?
- What is the target platelet dose, and how is it defined? Per shot, per microliter, or total across the course.
- Is the dose measured or assumed? Ask whether the final concentrate is counted, not guessed from the device specs.
- Leukocyte-rich or leukocyte-poor, and why? The answer should point to your target tissue.
- How are red cell contamination and pre-activation controlled? These are prep and handling questions that published research says matter.
- Where exactly is it being delivered, and on what hypothesis? Whether it goes into the joint, the bone, under the cartilage, or the disc should follow a stated reason.
- How will response be judged, and when would the plan change? Agree on the checkpoints before the first shot, not after the third.
Regen.MD is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport. Details are on our St. Louis clinic page. The first step is a physician-led Clinical Evaluation.
For more information, get our free guide to knee pain and treatment options.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
What this practice actually uses
We do not leave the questions above open. Regen.MD makes platelet-rich plasma leukocyte-poor — no white blood cells and no red blood cells. It is activated with calcium chloride. The platelet concentration is two to three times baseline, with higher dosing in the six to twelve times range.
The target is a measured dose of more than ten billion platelets per joint. It is measured, not assumed. Platelet yield varies between patients and between blood draws. That is why a protocol stated only as a multiple of baseline can give very different actual doses to two people on the same day. That is the practice’s standard, not a finding from any single trial.
Frequently Asked Questions
Is there a platelet dose that matters most?
In sports medicine, including osteoarthritis, tendon problems, and muscle injury, a 2025 review reports the best results above 3.5 billion platelets per shot. It reports total doses of 10 to 12 billion across a course. That is a target from a review, not a rule for every patient. So the useful step is to ask how your own protocol defines and checks the dose. The delivery options are described on our orthobiologics services page.
Which preparation factors have the biggest effect?
The published ones are white cell content, red blood cells mixed in, and activating too early while it is made. All of these change what is really injected, not just how it is labeled. How we build those factors into a plan is laid out in our approach to clinical evaluation.
Why did my first injection help more than my second?
There is no proven explanation for that pattern. Anyone who offers you a confident one is going past the evidence. Differences in prep, delivery target, and what else changed in your rehab could all play a part. The honest answer is that it needs a fresh look, not a repeat. That is where the conditions we evaluate and the first diagnosis get revisited.
Does intraosseous or subchondral delivery work better than a standard injection?
They are not upgrades. They are different targets, chosen when the medical idea points at structures near the bone, not the joint space. Dose and prep still decide what arrives there. Where PRP sits next to bone marrow aspirate concentrate and Lipogems is covered on our orthobiologics services page.
Can peptide medicine be part of the same plan as PRP?
It can be part of the same talk, but it is assessed separately. Here it is a medical and teaching topic, not a product for sale. The approach is on our peptide therapy page.
Do PRP injections actually work?
PRP works when the shot delivers enough platelets and the concentrate was made well. A 2025 review reports the best results above 3.5 billion platelets per shot, with 10 to 12 billion across a course. Regen.MD targets a measured dose of more than ten billion platelets per joint. In advanced knee arthritis, PRP is a bridge before joint replacement, not a way to regrow cartilage.
Who is not a good candidate for PRP?
Two things change what PRP can do for you. When imaging shows advanced joint disease, the goal shifts. PRP becomes a bridge before joint replacement, not a repair. When your joint pain tracks with metabolic stress instead of activity, a shot alone tends to give short-lived relief. So the metabolic work runs alongside it. A physician-led Clinical Evaluation sorts out which applies to you.
Is there anything better than PRP?
Not better so much as different. Bone marrow aspirate concentrate, Lipogems and shots into the disc are separate tools with different targets. The choice follows a medical idea about what is causing your pain, not a ranking of products. When conservative care has truly run its course, surgery is available here, because Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon.
How many times can you get a PRP shot?
There is no fixed number. Research describes total doses of 10 to 12 billion platelets across several treatments. So a course may involve more than one shot, but each one follows medical need. We treat PRP as a process with checkpoints. Agree on how response will be judged, and when the plan would change, before the first shot, not after the third.
Sources
- Corsini A, Perticarini L, Palermi S, Bettinsoli P, Marchini A, “Re-Evaluating Platelet-Rich Plasma Dosing Strategies in Sports Medicine: The Role of the ’10 Billion Platelet Dose’ in Optimizing Therapeutic Outcomes — A Narrative Review,” Journal of Clinical Medicine, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12027823/ — referenced for the platelet dose thresholds (above 3.5 billion per injection, 10 to 12 billion cumulative) in musculoskeletal sports medicine indications; for leukocyte-poor PRP demonstrating superior efficacy to leukocyte-rich PRP in intra-articular use while remaining debated in tendon and muscle; for red blood cell contamination and pre-activation being detrimental to effectiveness; for the low rate of comprehensive protocol description and quantitative composition reporting in published PRP trials; and for the methodological error and reliability findings in the PRP literature.
- “Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy,” Scientific Reports, volume 11, article 3971, 2021, https://www.nature.com/articles/s41598-021-83025-2 — randomized study of 150 patients with knee osteoarthritis. Referenced for the finding that adding a 1 micron filtration step to manual PRP processing improved platelet recovery to as much as 90%. Note: this paper has a published Author Correction (https://www.nature.com/articles/s41598-021-98365-2) relating to incorrect MRI images in Figure 3; the correction does not affect the preparation finding cited here.